Northern Trust Corp purchased a new stake in Upstream Bio, Inc. (NASDAQ:UPB) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 143,721 shares of the company’s stock, valued at approximately $2,363,000. Northern Trust Corp owned about 0.27% of Upstream Bio at the end of the most recent quarter. \n\nA number of other institutional investors have also made changes to their positions in UPB. FMR LLC bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $117,977,000. Decheng Capital LLC bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $54,010,000. Bain Capital Life Sciences Investors LLC bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $37,735,000. Wellington Management Group LLP bought a new stake in shares of Upstream Bio in the 4th quarter valued at approximately $25,632,000. Finally, Alliancebernstein L.P. bought a new position in Upstream Bio during the 4th quarter worth $18,270,000. \n\nShares of UPB opened at $9.16 on Monday. The stock has a fifty day moving average price of $8.04 and a 200 day moving average price of $12.26. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46. \n\nUpstream Bio (<NASDAQ:UPB> – Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.71 million. On average, equities analysts forecast that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year. \n\nUpstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

Northern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)

Northern Trust Corp and other institutional investors increased their stakes in Upstream Bio, Inc. (NASDAQ:UPB) in the fourth quarter, with Northern Trust purchasing 143,721 shares valued at $2.36 million. The company reported Q1 earnings of ($0.51) EPS, missing analyst estimates, and operates in biotechnology to develop treatments for respiratory and inflammatory diseases.